|Videos|December 22, 2022
Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer
Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
The top 5 OncLive TV videos of the week cover insights in endometrial cancer, mCRPC, germ cell tumors, melanoma, and HNSCC.
Sac-TMT extended survival and improved response rates vs chemotherapy in endometrial cancer that had progressed after chemotherapy and immunotherapy.
Single-agent pembrolizumab extended progression-free survival vs carboplatin and paclitaxel in mismatch repair–deficient endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5